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Objectives. This study sought to evaluate the delivery e~iciency, 
intramural retention and antirestenotic efficacy of soluble colchi. 
cine or a colchicine analogue delivered into the arterial wall after 
angioplasty as well as the efficacy of these medications after 
prolonged local release from biodegradable micropartieles. 
Background. Local delivery of pharmacologic agents is a poten- 
tial treatment for restenosis. However, the delivery efficiency of the 
technique and the choice of agent to modulate cellular prolifera- 
tion are unknown. It was hypothesized that restenosis would be 
unaffected by colchicine or a hydrophobic colehicine analogue 
with short intramural retention, whereas it would be reduced after 
prolonged local release. 
Methods. Rabbit atherosclerotic femoral arteries underwent 
angioplasty followed by local delivery. Delivery efficiency and 
intramural retention of 3H-colchicine were evaluated. The effect of 
agents in soluble formulation or released from microparticles on 
angiographic and morphometric restenosis was evaluated at 2 
weeks and compared with that in the control groups (angioplasty 
only and local infusion of carrier solution). 
Results. Delivery efficiency was 0.01% and intramural retention 
<24 h. Neither soluble colehicine formulation reduced restenosis. 
Microparticles releasing the colehicine analogue reduced reste- 
nosis compared with control and colchicine microparticles but not 
angioplasty alone (p = 0.002). Delivery outside the artery was 
observed, and the long.term release of both colchicines resulted in 
toxicity to the adjacent musculature. 
Conclusions. Colchicine or the colchicine analogue did not 
reduce restenosis, although the long-term local release of the 
colchicine analogue reduced neointimal proliferation resulting 
from local delivery. Local delivery of cytotoxic agents with insuf- 
ficient vascular specificity may be limited by toxicity to adjacent 
tissues resulting from a larger than expected delivery area and 
prolonged agent retention. 
(J Am Coil Cardiol 1995;26:1549-57) 
No pharmacologic agent has reduced the rate of restenosis in
humans after percutaneous transluminal coronary angioplasty. 
Colchieine is a potential antirestenotic agent because it has 
demonstrated antiproliferative properties in both bovine and 
human smooth muscle cell cultures (1,2). However, aclinical 
trial evaluating the efficacy of oral colchicine did not demon- 
strate a reduction in the rate of coronary restenosis, possibly 
reflecting an inability to achieve an effective intramural drug 
From the Krannert Institute of Cardiology, Department of Medicine, 
Indiana University School of Medicine, Indianapolis, Indiana; *Advanced Car- 
diovascular Systems, Santa Clara, California; and ?Eli Lilly and Company, 
Greenfield, Indiana. This study was supported in part by a sponsored research 
agreement between the Krannert Institute of Cardiology and Eli Lilly and 
Company (Drs. March, Wilensky and Hathaway) and a Grant-in-Aid to Dr. 
Wilensky from the American Heart Association (Indiana Affiliate), Indianapolis. 
It was presented in part at the 65th and 66th Annual Scientific Sessions of the 
American Heart Association, New Orleans, Louisiana, November 1992 and 
Atlanta, Georgia, November 1993. Drs. Wilensky, March and Hathaway own the 
patents on the delivery of biodegradable microparticles in the arterial wall as well 
as the catheter. 
Manuscript received January 26, 1995; revised manuscript received June 16, 
1995, accepted June 21, 1995. 
Ad~lress for correspondence: Dr. Robert L. Wilensky, Krannert Institute of 
Cardiology, 1111 West 10th Street, Indianapolis, Indiana 46202-4800. 
level. Oral administration was further limited by the systemic 
side effects of coichicine (3). Given colchicine's antimitotic 
properties, the agent may be effective inreducing restenosis in
the presence of adequate and prolonged vascular tissue levels. 
Because restenosis localized, systemic toxicity can be 
overcome by the direct intramural delivery of antirestenotic 
agents. Several porous infusion balloon catheters have been 
developed for site-specific delivery (4); however, delivery effi- 
ciency is low, and intramural retention time of infused agents 
is short (5-8) and may be inadequate to modulate vascular 
smooth muscle cell proliferation. Incorporation of active 
agents into biodegradable microparticles and the subsequent 
intramural delivery of the microparticles-agent combination 
may be a potential approach to increase the intramural reten- 
tion of pharmacologic or genetic agents. Intramural delivery 
and prolonged retention of microparticles (>2 weeks) into and 
around the arterial wall have been demonstrated using porous 
catheters (9,10). Biodegradable microparticles incorporating 
colchicine or a hydrophobic colchicine analogue subsequently 
releasing these agents over several weeks decrease smooth 
muscle cell proliferation i vitro (2). Therefore, the purpose of 
this study was twofold: 1) to evaluate the delivery efficiency, 
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Figure 1. Experimental design. PB/ME = porous 
balloon/mechanical expansion catheter; PTA = percu- 
taneous transluminal ngioplasty. 
intramural retention and efficacy of soluble colchicine or a 
colchicine analogue delivered into the arterial wall on reste- 
nosis; and 2) to evaluate the safety and efficacy of these agents, 
which were incorporated into biodegradable microparticles 
and delivered locally to restenotic lesions after angioplasty in
atherosclerotic rabbit femoral arteries. 
Methods  
Experimental design. All procedures were in accordance 
with Indiana University Animal Resource Committee guide- 
lines, and studies were approved by an independent review 
board. Data were obtained from three consecutive substudies 
(Fig. 1) determining: 1) delivery efficiency and local retention 
of liquid colchicine; 2) efficacy of colchicine or a colchicine 
analogue solution in reducing restenosis; and 3) efficacy of 
prolonged elivery of colchicine or a colchicine analogue on 
restenosis. For the studies evaluating efficacy of colchicine or 
the colchicine analogue (items 2 and 3), arteries were random- 
ized into three groups: 1) a control group that underwent 
angioplasty only; 2) a control group that underwent both 
angioplasty and intramural infusion of the carrier solution; and 
3) the experimental groups that underwent angioplasty and 
local infusion of the agents, either in soluble formulation or 
released from biodegradable microparticles. In animals that 
underwent local infusion of microparticles containing active 
agents, the contralateral rtery was infused with the carrier 
solution, consisting of a suspension containing nondrug-loaded 
microparticles. These control groups were used to evaluate the 
long-term effects of local infusion and the effect of the retained 
biodegradable polymer material. 
Infused medications. Titrated colchicine. One milliliter of 
tritiated colchicine (New England Nuclear) at a concentration 
of 10 /amolhiter and an activity of 2/~Ci/ml was infused to 
evaluate local delivery and intramural retention variables of 
liquid colchicine. 
Solubilized agents for studies of efficacy. One milliliter of 
crystalline colchicine dissolved in normal saline solution was 
administered in two dose regimens: 0.1 txmol/liter (n = 8, low 
dose) and 10 t~mol/liter (n = 9, high dose). Alternatively, 1 ml 
of a hydrophobic colchicine analogue (LY 150832) suspended 
in a liposomal carrier emulsion was infused at a concentration 
of 10/xmol/liter (n = 18). 
Microparticles containing colchicine. Sterile poly(lactic 
acid-glycolic acid) microparticles containing either colchicine 
or colchicine analogue as well as control microparticles were 
obtained from Polymicrospheres, Inc. Microparticles contain- 
ing colchicine had 8% to 10.5% (average 9.25%) active agent 
content by weight, with 80% of the mieroparticle diameters 
ranging from 6 to 8/xm. Microparticles containing the colchi- 
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cine analogue had 16% active agent content by weight, with 
80% of the particle diameters ranging from 5.5 to 7/zm (2). 
The median effective concentration (ECs0) for biodegradable 
micropartides containing colchicine was 0.02/xg/ml in bovine 
smooth muscle cell culture after incubation for 48 h. The ECso 
for biodegradable microparticles containing the colchicine 
analogue was 0.15 /zg/ml. Microparticles were stored as a 
desiccated powder until use, at which time they were sus- 
pended in 0.9% normal saline solution and 0.25% Tween 80. 
The resulting microparticle concentration was 10 mg/ml, with 
an average particle count of 1.4 x 108 microparticles/ml. The 
suspension was sonicated for 10 min immediately before 
infusion to reduce aggregation. 
Induction of atherosclerosis. New Zealand white rabbits of 
either gender were fed a normal diet. When they weighed 3.5 
to 4.5 kg, they were anesthetized with an intramuscular injec- 
tion of ketamine (100 mg/kg body weight) and xylazine 
(14.2 mg/kg). Bilateral focal atherosclerosis n the femoral 
arteries was induced by air desiccation (11) of an exposed and 
isolated 5-mm arterial segment. Arterial desiccation was 
achieved by passing air through the segment for 8 min at a flow 
rate of 80 ml/min. The ligatures were then relieved, and blood 
flow was restored. A metal clip was positioned in the overlying 
muscle layer to aid in subsequent balloon placement and 
histologic evaluation. The rabbits were then placed on an 
atherogenic diet of 2% cholesterol, 6% peanut oil at 150 g/day 
for 3 weeks. The resulting lesion was focal and consisted of a 
heterogeneous mixture of foam cells and smooth muscle cells 
(12). 
Angioplas~/infusion. The rabbits were anesthetized as de- 
scribed. Angiography and angioplasty were performed as pre- 
viously described (13). Briefly, angioplasty was performed in 
nonoccluded arteries demonstrating >20% stenosis with a 
minimally compliant balloon catheter (Advanced Cardiovascu- 
lar Systems) <0.5 mm larger in diameter than the proximal, 
nonatherosderotic arterial segment. The angioplasty balloon 
was inflated to 10 atm for 1 min and deflated for 1 rain with the 
cycle repeated for a total of three inflations. A postprocedural 
angiogram was obtained, and arteries exhibiting aneurysm 
formation were excluded from further study. Aneurysm forma- 
tion was defined as a discrete saccular outpouching of the 
arterial lumen in relation to the lumen of the nonatheroscle- 
rotic arterial segment. Arteries that underwent successful 
angioplasty were randomized into the experimental nd two 
control groups. The average balloon/artery ratio was 1.29. 
Delivery efficiency and retention were evaluated by infusion 
of 1 ml of 3H-colchicine (activity 2 p~Ci/ml) with a standard 
porous balloon catheter containing 50 holes, each 25 /~m in 
diameter (Fig. 1). Expansion of the balloon as well as local 
infusion were performed at 6 atm of hydraulic pressure. 
Infusion was performed in the identical location as the pre- 
ceding angioplasty with an infusion catheter of equal nominal 
diameter to the angioplasty catheter. The procedure was 
repeated in the contralateral rtery using a new infusion 
catheter. Rabbits were killed immediately and 20 min after 
delivery and 1, 2, 3, 5 and 7 days after infusion. 
Arteries receiving liquid colchicine also underwent local 
delivery using a standard porous balloon catheter. The infusion 
catheter, of equal nominal diameter to the angioplasty cathe- 
ter, was placed in the area of previous angioplasty, and 1 ml of 
either colchicine or colchicine analogue was infused at 6 atm of 
pressure. The catheter was then removed, and an unused 
catheter was placed into the contralateral artery. One milliliter 
of control carrier fluid was then infused. The catheter was 
removed, and the follow-up angiogram was obtained. 
Previous unpublished observations revealed significant 
plugging and decreased delivery of 5-txm microparticles when 
utilizing the standard porous balloon catheter; therefore, in 
arteries receiving either microparticle suspension, a porous 
balloon/mechanical expansion catheter was used. The porous 
balloon/mechanical expansion catheter uses a braided wire 
cage covered by a balloon with 50 pores, each 65 /,m in 
diameter. Expansion of the mechanical cage permits position- 
ing of the infusion balloon against he vascular wall before 
infusion. Infusion is independent of expansion, resulting in 
significantly decreased intraluminal delivery into the target 
vessel (10). After angioplasty and randomization, the porous 
balloon/mechanical expansion catheter, oversized 0.5 mm 
larger than the angioplasty balloon catheter, was placed into 
the area of previous angioplasty, and the undergirding was 
expanded. The average porous balloon/mechanical expansion 
to artery ratio was 1.58. Infusion of 2 ml of the microparticle 
suspension containing either colchicine or the colchicine ana- 
logue was performed at a pressure of 4 atm (Fig. 1). The 
contralateral rteries were infused with 2 ml of the control 
microparticle suspension at the same pressure and volume but 
with a new catheter. A postinfusion angiogram was obtained, 
the sheath was removed, and the artery and skin were sutured. 
The rabbits were placed on a normal diet for 2 weeks until death. 
Animal death. The rabbits were anesthetized with ket- 
amine and xylazine, and vascular access was obtained in the 
distal abdominal aorta and inferior vena cava, as previously 
described (13). The animals were then killed with an overdose 
of pentothal and an infusion of formalin was started at 
90 mm Hg. The arteries were obtained en bloc, placed in 
formalin, dissected from the overlying muscle layers and cut 
into 2-mm long segments, and the distal end of each segment 
was marked with a dot of India ink. The segments were 
numbered and placed in individual boxes for histologic pro- 
cessing. Sections from the skeletal musculature overlying the 
infusion site were collected in the microparticle substudy to 
evaluate the local effects of toxicity of colchicine or the 
colchicine analogue or the biodegradable polymer comprising 
the microparticle. 
Radiographic analysis. Radiograms obtained before and 
after angioplasty, after infusion and at the time of death were 
examined for the presence of dissections and signs of aneurysm 
formation. The following measurements were obtained: 1) 
minimal umen diameter = lumen diameter in the area of 
greatest stenosis; 2) proximal lumen diameter = lumen diame- 
ter of the normal segment proximal to the lesion; and 3) distal 
lumen diameter = lumen diameter distal to the lesion. Percent 
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maximal stenosis was calculated using the following formula: 
(Proximal lumen diameter - Minimal lumen diameter/ 
Proximal lumen diameter) x 100. In addition, the minimal 
lumen diameter of the common iliac artery, obtained from the 
final angiogram, was measured and compared with the same 
location on the initial angiogram to evaluate the effect of the 
multiple passage of catheters through proximal nonatheroscle- 
rotic vessels. Radiographic differences between groups were 
evaluated using analysis of variance. Differences in iliac artery 
radiographic stenosis were analyzed using the Student t test. A 
p value < 0.05 was considered significant. 
Tritiated colchicine samples and measurements. Arteries 
(n = 21) infused with the tritiated colchicine solution were 
obtained unfixed at eight time points after infusion: immedi- 
ately, 20 min, 5 h and 1, 2, 3, 5 and 7 days. Additional tissue 
samples were obtained from the distal artery, liver and ilium as 
well as blood to evaluate the systemic presence of radioactivity. 
The artery, -20 mm in length, as well as the other tissues, was 
cleaned of the overlying musculature and placed in 3 ml of a 
2 mol/liter sodium hydroxide solution until the tissue dissolved. 
Aliquots of 200 txl of tissue solution plus 1 ml of 0.25 mol/liter 
Tris buffer (pH 7.1) and 10 ml of scintillation fluid were placed 
in scintillation vials, and the radioactivity was measured. An 
aliquot of the infusate solution was measured as a control. 
Results were corrected for background radioactivity, tissue 
weight and amount of injected radioactivity. Results are ex- 
pressed as counts/g of arterial tissue. 
Histologic processing/morphometric analysis. After paraf- 
fin embedding, a 5-/zm thick section from each arterial seg- 
ment was obtained and stained with hematoxylin and eosin 
and a combined Gomori's aldehyde fuchsin with a trichrome 
counterstain. All segments of each artery were evaluated and 
measured except for those with processing artifacts or side 
branches (52 [3.2%] of 1,604 total segments). Measurements of 
the circumference of the arterial lumen, internal elastic lamina 
and external elastic lamina were performed using the 
Macintosh-based NIH IMAGE software package after hand 
tracing of the lumen and internal and external elastic laminae 
boundaries. Lumen and neointimal and medial areas were 
calculated. 
In many of the arterial sections, substantial internal elastic 
lamina injury was seen, making the unambiguous measurement of 
neointimal area impossible. For these sections the summed 
neointimal and medial areas were calculated as the area within 
the external elastic lamina minus the lumen area. Such segments 
accounted for 18% of the total number of segments but were 
often those containing the greatest neointimal plus medial area 
value for a given artery. Use of the segment with the maximal 
neointimal rea as the reference segment would bias the results 
by eliminating from evaluation the most diseased segment, pos- 
sessing significant internal elastic lamina disruption and poten- 
tially the largest neointimal plus medial area. 
The relation between maximal intimal area and arterial 
size, as defined by the external elastic laminal circumference, 
was first evaluated in control arteries within the liquid colchi- 
cine substudy (r = 0.60, p = 0.002). A similar correlation 
between neointimal plus medial area and external elastic 
laminal circumference was observed in both the liquid colchi- 
cine and colchicine microparticle studies (r = 0.51, p < 0.001; 
r = 0.64, p < 0.001, respectively). Because a significant, 
positive correlation between eointimal plus medial area and 
vessel size was observed, analysis of covariance was used to 
adjust for individual differences in artery size and to compare 
the neointimal p us medial areas for the treatment groups. The 
adjustment for individual differences in artery size was used 
because a range of vessel sizes within a sample group will 
obscure differences in neointimal plus medial areas, and any 
statistical conclusion may represent differences in vessel size 
rather than a treatment effect. External elastic laminal circum- 
ference rather than the area bounded by the external elastic 
lamina was used to define vessel size because this measure- 
ment is not dependent on a fixed artery possessing perfect 
circularity. 
Approximately fourteen 2-ram segments were obtained 
from each artery centered around the area of the original 
lesion. The number of segments exhibiting intimal formation 
was determined toassess whether the passage of the local drug 
delivery catheter led to intimal proliferation i hitherto normal 
segments. Because the original esion is discrete (typically 5to 
8 mm in length), an increase in the number of segments per 
artery exhibiting intimal proliferation represents additional 
injury resulting from balloon passage or the angioplasty/ 
delivery process, or both. 
Samples of skeletal muscle adjacent o the area of the 
femoral artery infused with microparticles were examined for 
pathologic changes resulting from local infusion. Samples were 
obtained from the most grossly fibrotic areas. The sections 
were read in blinded manner and graded 0 to 4 according to 
lesion severity: grade 0 = no pathologic hanges; grade 1 = 
minimal severity; grade 2 : slight severity; grade 3 = moderate 
severity; and grade 4 = severe local pathologic hanges. All 
samples were graded for the presence of multifocal myofiber 
degeneration a d regeneration, necrosis and atrophy, multifo- 
cal phagocytosis, chronic inflammation a d interstitial fibrosis. 
Multifocal myofiber regeneration was defined as the presence of 
multiple nuclei within a myofiber with increased basophilic 
cytoplasm. Phagocytosis was graded as the presence of enlarged 
macrophages with distended cytoplasm. Skeletal muscle ob- 
tained from animals that underwent angioplasty without local 
infusion was used as a control. Muscle toxicity of control 
microparticles and microparticles containing colchicine and 
colchicine analogue was evaluated by the Jonckheere-Terpstra 
test for differences inthe distribution of ordered values among 
groups. 
Results  
Delivery and retention characteristics of hydrophUic ol- 
chicine. A total of 21 arteries were infused with 1 ml of 
tritiated colchicine. Four arteries were obtained within 5 rain 
of infusion to evaluate the initial delivery efficiency of colchi- 
cine. Colchicine delivery into the vessel wall was calculated at 
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Figure 2. Mean intramural levels of 3H-colchicine over time. Imme- 
diately after infusion (n = 4), 0.01% of the infused colchicine was 
present within the arterial wall. Additional samples at 20 min (n = 3), 
5 h (n = 2) and 24 h (n -- 3) illustrate the rapid decline in intramural 
levels so that little intramural colchicine was measured ->24 h after 
infusion. Samples were also obtained at 2 (n = 2), 3 (n = 3), 5 (n = 2) 
and 7 days (n = 2) after infusion. 
0.01% of the total delivered ose. Figure 2 shows the relation 
between retained radioactivity and time after infusion (imme- 
diately, 20 min, 5 h, 1, 2, 3, 5, 7 days). A biphasic tissue 
elimination was calculated with an initial intramural half-time 
(tl/2) of 20 min, followed by a slower elimination phase of tl/2 
= 8 h. Essentially, all intramural radioactivity was lost within 
24 h. The arterial segment adjacent o the delivered segment 
immediately demonstrated 21.6% of the radioactivity of the 
infused segment on a weight to weight basis, whereas the ilium 
exhibited 11.5% and the liver 11.3%. Radioactivity of the 
blood was negligible. 
Lack of effect of locally delivered eolchicine and colchicine 
analogue on restenosis. A total of 64 arteries underwent 
angioplasty, of which 35 underwent infusion with colchicine or 
colchicine analogue solution; 20 contralateral patent arteries 
acted as control arteries and were infused with carrier solution 
only; and 9 underwent angioplasty without infusion. There was 
no statistically significant difference in radiographic minimal 
lumen diameter (Table 1) or stenosis before or after angio- 
plasty or at time of death between the groups. No significant 
difference in neointimal plus medial area was observed be- 
tween groups, indicating no effect of locally delivered soluble 
colchicine or colchicine analogue on restenosis. 
Local infusion with biodegradable microparticles releasing 
colchicine or colchicine analogue. Of the 106 arteries that 
underwent angioplasty, 10 were rejected from further study 
because of saccular aneurysm formation resulting from angio- 
plasty and 2 from local infusion of microparticles containing 
the colchicine analogue. Measurements from these arteries 
were excluded from further statistical analysis, leaving 94 
arteries for analysis: 18 infused with microparticles containing 
colchicine, 22 infused with microparticles containing colchicine 
analogue, and 30 infused with control microparticles; 24 
arteries underwent angioplasty only. 
No increase in short-term ortality related to the infusion 
procedure, and no increase in morbidity or mortality during 
the 2-week postprocedural period was noted. Animal discom- 
fort resulting from microparticle infusion into the extremities 
was not seen. No increase in late aneurysm formation resulting 
from the chronic, controlled release of colchieine from biode- 
gradable microparticles in the vascular wall was noted. 
Radiographic results showed no difference in minimal 
lumen diameter before or after angioplasty or at death in the 
four groups (Table 2). At death the minimal umen diameter 
was larger in the angioplasty-only group and the microparticle- 
releasing colchicine analogue group but did not achieve statis- 
tical significance. Morphometric data showed a similar mean 
neointimal plus medial area for the angioplasty-only group and 
microparticle-releasing colchicine analogue group, signifi- 
cantly smaller than the microparticle-releasing coichicine 
group and the control microparticle group (p = 0.002). 
There were no obvious histologic differences in arteries 
infused with microparticles or microparticles containing col- 
chicine or colchicine analogue. However, signs of local toxicity 
were observed in the muscle layers overlying and fed by 
arteries infused with the microparticles containing colchicine 
or colchicine analogue but not control microparticles (Fig. 3). 
Only 1 of 12 skeletal muscle samples from animals that 
underwent angioplasty showed pathologic hanges (Table 3). 
Skeletal muscle samples adjacent to the femoral arteries, which 
underwent local delivery of control microparticles (n = 24), 
had lesions consisting of minimal chronic inflammation (n = 
1), multifoeal small areas of phagocytosis (n = 11) and 
Table 1. Radiographic Minimal Lumen Diameters and Morphometric Results From Liquid 
Colchicine Substudy 
Pre-PTA Post-PTA Death Max N + M 
Group (mm) (mm) (mm) (mm z) 
PTA only (n = 9) 1.06 -+ 0.06 
Control solution (n = 20) 1.07 +- 0.05 
0.1 /zmol/liter colchicine (n = 8) 1.12 _+ 0.07 
10 ~mol/liter colchicine (n = 9) 1.03 _+ 0.04 
10/zmol/liter colchicine analogue 1.10 _+ 0.06 
(n = 18) 
1.28 _+ 0.06 1.00 _+ 0.09 0.954 + 0.150 
1.27 _+ 0.04 1.00 -- 0.08 1.365 _+ 0.100 
1.34 _+ 0.10 0.89 _+ 0.13 1.446 ___ 0.160 
1.31 _+ 0.05 0.94 _+ 0.10 1.272 ___ 0.149 
1.35 -- 0.05 1.08 +_ 0.04 1.406 ___ 0.106 
p = NS. Data presented are mean value +_ SE. Max N + M = maximal neointimal p us medial area djusted for 
vessel size; PTA = percutaneous transluminal angioplasty. 
1554 GRADUS-PIZLO ET AL. JACC Vol. 26, No. 6 
LOCAL DELIVERY OF BIODEGRADABLE MICROPARTICLES November 15, 1995:1549-57 
Table 2. Radiographic Minimal Lumen Diameters and Morphometric Results From 
Microparticle Substudy 
Pre-PTA Post-PTA Death Max N + M 
Group (mm) (mm) (mm) (mm 2) 
PTA only (n = 24) 
Control microparticles (n = 30) 
Micropartides releasing colchicine (n= 18) 
Micropartides releasing colchicine analogue (n= 22) 
1.19 _+ 0.04 1.40 _+ 0.04 1.02 _+ 0.06 0.737 +- 0.044* 
1.15 _+ 0.04 1.38 - 0.04 0.94 +_ 0.04 0.933 -+ 0.040 
1.18 _ 0.04 1.36 _ 0.04 0.94 -+ 0.05 0.953 -+ 0.052 
1.23 +_ 0.04 1.51 _+ 0.05 1.04 - 0.04 0.812 _+ 0.047* 
*p = 0.002 versus other groups. Data presented are mean value _+ SE. Abbreviations as in Table 1. 
multifocal areas of atrophic myofibers (n = 8). Thirteen 
samples had no histologic lesions. In contrast, all skeletal 
muscle fiber samples from the microparticle-releasing colchi- 
cine and colchicine analogue groups (n = 36) exhibited one or 
more pathologic lesions, all grossly visible as blanching. The 
incidence and severity of myofiber vacuolar degeneration a d 
regeneration, i terstitial fibrosis, inflammation, phagocTtosis 
and atrophy were significantly increased in the groups infused 
with microparticles containing active agents compared with 
those infused with control microparticles or undergoing angio- 
plasty only. 
Effect of catheter passage on neointimal formation. The 
mean minimal lumen diameter of iliac arteries obtained from 
rabbits that underwent femoral artery angioplasty only de- 
creased by 16% in the 2 weeks between angioplasty and death, 
whereas passage of the standard porous balloon catheter in 
addition to the angioplasty catheter resulted in a 21% decrease 
(p = NS). The combined passage of the porous balloon/ 
mechanical expansion and angioplasty catheters caused a33% 
reduction in minimal umen diameter (p < 0.001 compared 
with the angioplasty only group). The minimal umen diame- 
ters were (mean - SE) 1.72 _ 0.07 mm for the angioplasty- 
only group, 1.56 --- 0.05 mm for the angioplasty plus porous 
balloon passage group and 1.41 ___ 0.04 mm for the angioplasty 
plus passage of the porous balloon/mechanical expansion 
catheter group (p = 0.004) versus other groups. Histologic 
evaluation of the iliac arteries revealed that the reduction in 
minimal lumen diameter esulted from diffuse neointimal 
formation (data not shown). In addition, femoral arteries that 
underwent angioplasty and local infusion with the porous 
balloon/mechanical expansion catheter had an increased num- 
ber of segments per artery exhibiting neointima (p < 0.001), 
suggesting increased arterial injury associated with the passage 
of the catheter or local infusion, or both. In total, 70.5 +_ 5.6% 
of arterial segments exhibited neointima 2 wk after angio- 
plasty, whereas 92.9 _+ 1.7%, 96.4 _+ 2.2% and 89.7 - 5.1% of 
arterial segments exhibited neointima fter angioplasty and 
local infusion with control microparticles, microparticles con- 
taining colchicine and microparticles containing the colchicine 
analogue, respectively (p < 0.001 angioplasty only vs. other 
groups). 
Discuss ion  
Colchicine reduces bovine and human coronary smooth 
muscle cell proliferation i cell culture (1,2). However, the oral 
t ' ,  
Figure 3. Effect of local intramural infusion of micropar- 
ticles containing a coichicine analogue on adjacent skeletal 
musculature. A, View of musculature of the upper thigh 
after emoval of the skin from a rabbit 2weeks after infusion 
of control microparticles. No pathologic changes are ob- 
served. The glistening area of the surface results from the 
reflection of light during photography. B, Contralateral leg, 
exhibiting a large area of tissue damage 2 weeks after 
infusion of microparticles containing the colchicine ana- 
logue (asterisk). Arrowheads denote location of femoral 
artery. The area of delivery may be surmised by the extent of 
blanched tissue. C, Example of minimal to moderate patho- 
logic changes resulting from controlled release of colchi- 
cine. Replacement of skeletal muscle fibers by fibrosis and 
phagocytosis can be seen. D, Example of severe local 
pathologic changes from a sample obtained from the leg 
shown in B. Extreme skeletal muscle atrophy, necrosis and 
regeneration as well as interstitial fibrosis and multifocal 
phagocytosis can be seen. C and D, Hematoxylin a d eosin 
×400, reduced by 30%. 
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Table 3. Mean Pathologic Changes inAdjacent Skeletal Muscle 2 Weeks After Local Infusion With Microparticles Containing Colchicine or 
Colchicine Analogue 
Multifocal Myofiber 
Vacuolar Multi focal Chronic Interstitial 
Group Degeneration Necrosis Regeneration Atrophy Phagocytosis Inflammation Fibrosis 
PTA (n : 12) 0 0 0 0.17 (1) 0,08 (1) 0 0.08 (1) 
Control microparticles 1.33 ~ 0.8 (6) 0.04 (1) 0.25 _+ 0.12 (4) 0.33 _+ 0.11 (8) 0.54 -+ 0.13 (11) 0,08 (1) 0.21 _ 0.10 (4) 
(n = 24) 
Microparticles 1.20 ± 0.24* (10) 0.07 (1) 1.13 _+ 0.26* (9) 1.27 _+ 0.27* (10) 1.60 _+ 0,26* (12) 0.33 ,+ 0,19' (3) 1.13 _+ 0.31' (8) 
releasing colchicine 
(n = 15) 
Microparticles 1.57 + 0.21" (18) 0.38 ,+ 0.15t (4) 1.57 _+ 0.21' (17) 1.67 -+ 0.21" (17) 2.24 ,+ 0,23* (19) 0.57 ___ 0.19' (9) 1.33 ,+ 0.22* (15) 
releasing colchieine 
analogue (n = 21) 
*p < 0.001, tp = 0.03 versus other groups. Data presented are mean ± SE pathologic grade for all samples in group; numbers in parentheses are histopathologic 
samples. PTA = percutaneous transluminal ngioplasty. 
administration f 1.2 mg/day of colchicine showed no effect on 
restenosis n humans (3), possibly reflecting inadequate dosing 
rather than an inherent lack of colchicine fficacy. Intolerance 
to the drug at this dosing level made further dosing increases 
impossible. Itwas therefore hypothesized that the local admin- 
istration and prolonged release of colchicine or colchicine 
analogue from biodegradable microparticles in the vascular 
wall after angioplasty would yield tissue levels adequate to 
reduce restenosis. 
Study results. 1) Delivery efficiency of hydrophilic olchi- 
cine was 0.01%; 2) locally delivered colchicine, a hydrophilic 
agent without specific vascular wall binding properties, was 
retained within the arterial wall for <24 h; 3) neither colchi- 
cine nor a colchicine analogue in liquid formulation reduced 
restenosis; 4) injury induced by the angioplasty and local 
infusion catheters resulted in increased neointimal prolifera- 
tion, both in the illac and the femoral arteries; 5) local 
administration f biodegradable microparticles with long-term 
release of a colchicine analogue reduced restenosis compared 
with local infusion but not angioplasty only; 6) local delivery 
was associated with a large delivery area outside the artery; and 
7) long-term release of colchicine and colchicine analogue 
from the microparticles resulted in substantial toxicity to the 
musculature adjacent to the artery. The results of this study 
indicate that a successful strategy of using local delivery to 
reduce restenosis must address two potential technical prob- 
lems: 1) the potentially toxic effect of the infused agent on 
adjacent issue, and 2) the additional vascular injury with 
subsequent increased neointimal formation resulting from 
passage of delivery catheters with increased profile or the local 
infusion procedure, or both. 
Lack of efficacy of colchicine and coichicine analogue. 
Effective local drug delivery for treatment ofatherosclerosis or 
restenosis depends on both efficient delivery and adequate 
retention of an effective agent. The latter, in turn, depends on 
the arterial transmural mass transport, he intrinsic biochem- 
ical binding and the diffusion properties of the infusate. 
Although the role of a porous balloon catheter design in 
delivery efficiency isnot fully defined, the current data showing 
a low delivery efficiency of colchicine are consistent with 
previously published ata (5,10) for both liquid medications 
and microparticles utilizing porous catheters. On the basis of 
the results hown, 1 ml of 10 ~mol/liter colchicine or colchicine 
analogue contained 4 tzg of active agent, and, assuming a
0.01% delivery efficiency, only 0.0004 txg of colchicine or 
colchicine analogue was delivered into the arterial wall. 
Because the greatest increase in the rate of angiographic 
restenosis (14,15) is the initial 3 months after angioplasty, 3 
months may represent the time necessary for pharmacologic 
agent retention. Although the issue of retention may not be 
important when an agent or genetic material that expresses a 
gene chronically or exhibits a long-lasting effect on cell cycle 
regulation (16) is delivered, for many pharmacologic agents, it
appears that delivery without subsequent prolonged retention 
will have little effect on restenosis. Retention of the colchicine 
was <24 h, too short to modulate smooth muscle cell prolif- 
eration. Several investigators using a variety of porous balloon 
configurations have demonstrated a short intramural retention 
time after local infusion. Retention of heparin is <2 days (6), 
and >67% of infused methotrexate is released from the 
arterial wall within the first days (5). Less than 1% of infused 
forskolin is present in the arterial wall 2 h after infusion (7), 
and the retention time of hirudin is also limited (8). The 
demonstrated transient intramural retention of colchicine may 
result from the arterial wall mass transfer properties and may 
be partly responsible for the lack of local observed effect. It is 
postulated that the initial intramural half-life of 20 rain may 
represent a mass transfer through the arterial wall, whereas the 
subsequent intramural elimination phase may have resulted 
from transient issue binding and release or diffusion of 
colchicine in the arterial wall. Nonetheless, the intramural 
residence time was <24 h, indicating that the local delivery of 
liquid agents that do not exhibit enhanced intramural binding 
result in neither a high delivery efficiency nor substantial 
long-term retention. To increase intramural retention, biode- 
gradable microparticles xhibiting a delivery efficiency similar 
to or higher than liquid agents and possessing prolonged in 
vivo retention time were developed (9). 
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Efficacy of local, long-term release of colchicine analogue. 
It has previously been shown (10) that the intravascular 
delivery efficiency for micropartieles 11.5 pm in diameter 
delivered with porous balloon/mechanical expansion catheter 
was 0.16%. Twenty milligrams of biodegradable microparticles 
containing 9.25% of colchicine or 16% of colchicine analogue 
by weight had a total of 1.85 mg of colchicine and 3.2 mg of 
colchicine analogue, respectively. Assuming the same delivery 
efficiency, 2.96 ~g of colchicine and 5.1 /~g of colchicine 
analogue were depositioned intramurally through the biode- 
gradable microparticles. Assuming a linear release of colchi- 
cine and colchicine analogue over 30 days, as described invitro 
(2), the intramural release of colchieine was 0.1 ~g/day, and that 
of colehicine analogue was 0.17 ~g/day. The observed efficacy 
of the colchicine analogue compound in reducing intimal 
proliferation may reflect he decreased intramural washout of 
hydrophobic colchicine after release from the micropartieles. 
Efficacy was observed only in relation to the control micropar- 
ticles and microparticles containing colchicine, indicating that 
microparticles releasing the colchicine analogue had an effect 
that approximately balanced the added neointimal formation 
resulting from the induced injury by the local infusion catheter. 
However, the cytotoxic activity of colchicine analogue did not 
obviate the reaction to vascular injury caused by angioplasty 
because no significant difference in neointimal plus medial 
area was observed compared with the angioplasty only group. 
Implications for local drug delivery. Porous balloon cath- 
eters were designed to facilitate the site-specific delivery of 
potentially toxic medications into the arterial wall while mini- 
mizing systemic side effects. Taken with previous tudies (10), 
the current data indicate that delivery of either liquid or 
microparticles using a porous catheter is possible but is not 
fully site specific, with substantial delivery of agents noted in 
the overlying musculature. Any strategy involving local delivery 
using catheters of similar design must address three potential 
limitations of the technique: 1) low delivery efficiency and 
inadequate intramural retention of liquid drug solutions, 2) a 
potentially toxic effect of the delivered agent on adjacent 
tissues, and 3) the effect of local drug delivery on the vessel. If 
the infused agent is sufficiently retained, binds to or is trans- 
ported into the smooth muscle cells and is an effective and 
specific cytostatic or cytotoxic agent, then the low delivery 
efficiency and retention may be overcome. In the absence of a 
sustained elivery system, enhanced intramural retention may 
be achieved by selective binding to endothelial or smooth 
muscle cells or the extracellular matrix. 
The rate of delivery (4 atm) was specifically chosen to 
ensure adequate delivery at a pressure at which the catheter 
did not exhibit "jetting" but "oozing" (unpublished observa- 
tions) because there is some evidence that high pressure 
"jetting" may cause additional vessel injury (17). Two millili- 
ters was chosen to ensure adequate intramural delivery; how- 
ever, the optimal delivery volume is unknown. It is conceivable 
that with increased elivery efficiency, a lesser volume may 
prove adequate. With improvements in catheter design and a 
greater understanding of the mechanism of local drug delivery, 
the vascular injury resulting from local delivery may be mini- 
mized by reducing the infusion pressure and volume. 
Local toxicity (Table 3) may have resulted from the sus- 
tained release and high local concentration of a toxic medica- 
tion, local ischemia resulting from embolization i to the local 
microvasculature by the microparticles or the effects of the 
breakdown of poly-D,L-lactide-co-glycolide into lactic and gly- 
colic acids and the resulting acidic milieu. However, in that the 
extent of toxicity resulting from the local infusion of experi- 
mental microparticles greatly exceeded the effect of control 
microparticles, the observed toxicity probably resulted from 
the controlled, long-term release of colchicine or the colchicine 
analogue rather than microparticle breakdown or the ischemic 
effect. Toxicity of biodegradable microparticles appears to be 
less than the arterial inflammatory esponse reported to result 
from biodegradable stents (4). The absence of local toxicity 
observed after liquid colchicine or colchicine analogue infusion 
resulted from the lack of retention of this formulation. 
The current study also substantiates previously presented 
data (10) indicating that microparticles can be delivered to the 
adjacent musculature from the arterial umen as a result of 
delivery into the microvasculature nourishing the arterial wall 
and adjacent issue. Adventitial placement and delivery of 
medication has been exploited to reduce lumen thrombus 
formation (18) and intimal proliferation in nonatherosclerotic 
rats (19,20), and it has been postulated that the intimal delivery 
of these agents resulted from flow through the vasa vasorum. 
Thus, the deposition of an agent bound to microparticles into 
the adventitial microvasculature is a potential method of local 
delivery. In addition, genetic manipulation of myocardium ay 
be possible utilizing porous catheters in the vessels upplying 
the area of interest. 
Study limitations. Intramural drug levels were not mea- 
sured and are unknown. The release properties of colchicine 
and the colchicine analogue from microparticles, although 
well-characterized in vitro (2), are unknown in vivo. Biode- 
gradable microparticles release colchicine and colchicine ana- 
logue in vitro over several weeks, but in vivo properties of 
biodegradable microparticles may differ because cellular ef- 
fects on hydrolysis and an inflammatory eaction to micropar- 
ticles might play a role in drug release. An enhanced rapid 
initial release of colchicine and colchicine analogue from 
microparticles in vivo might lead to high transient intramural 
levels of colchicine with subsequent rapid transport out of the 
arterial wall. Alternatively, inflammation leading to micropar- 
tide encapsulation may result in a slower than expected 
release. It is possible that a systemic effect of locally delivered 
colchicine or colchicine analogue reduced potential differ- 
ences in maximal neointimal and medial areas between 
experimental and control groups. Other tissues exhibited 
11.3% to 21.6% of the radioactivity delivered into the 
arterial site on a weight to weight basis. Finally, because 
these studies were performed in atherosclerotic rabbit fem- 
oral arteries, which are thin walled, the results may not be 
directly applicable to the thicker, more muscular atheroscle- 
rotic human coronary or peripheral vessels. 
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Conclusions. An effect on catheter-induced neointimal 
proliferation was observed after local delivery of micropar- 
ticles releasing a colchicine analogue. However, colchicine, 
whether delivered in an aqueous olution or incorporated into 
biodegradable microparticles, did not reduce restenosis. Local 
delivery using a porous catheter is inherently inefficient, and 
the local delivery of agents lacking vascular specificity may be 
limited by local toxicity resulting from microvascular delivery 
and retention of microparticles in the overlying tissue layers. 
We gratefully acknowledge the assistance ofDavid Mendel, BA, Linda Smith, BS 
and R. Gerald Dreessen, RRT as well as the secretarial assistance of Linda 
Rohyans. 
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